A Review of Multiple Myeloma Trials That Impact the Standard of Care

摘要

COSTELLO: I've said before that daratumumab [Darzalex] is the gift that keeps on giving, because [studies] keeps showing the importance of including this drug in every step of our treatment regimens. The GRIFFIN study that was updated at ASH included 24 months of maintenance for these patients and showed what we were expecting. That is that the addition of daratumumab to the triplet of RVd [lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone], both done in induction and followed by consolidation, followed by randomized daratu-mumab-lenalidomide vs lenalidomide maintenance, showed a continued deepening of response after consolidation through maintenance.